Mohit Trikha
Chief Executive Officer Kivu BioScience, Inc.
Dr. Mohit (Mo) Trikha is the CEO of Kivu Bioscience. He brings over 25 years of drug development expertise in oncology. He has been instrumental in advancing more than 40 programs from target identification to clinical trials in oncology. Previously, Mo was a venture partner at Apple Tree Partners, and also led oncology early development at AbbVie, where he oversaw the development of discovery-stage programs to clinical proof of concept, focusing on ADCs, bispecifics, and CAR-T therapies. He has contributed to the development of key drugs such as Kadcyla, Polivy, and vismodegib, and chaired collaborations with leading institutions like TeneoBio, Calibr, and The Scripps Research Institute. Earlier in his career, he held roles at Genentech, Centocor/Johnson & Johnson, and Triphase Accelerator. Mo earned his B.S. in Biochemistry from California State University, Los Angeles, and his PhD in Biochemistry and Molecular Biology from the University of Southern California.
Seminars
- Investigating ADC case studies in early clinical development to understand how ADC preclinical profiles translate to patient impact
- Breaking down strategies from ADC case studies to best set up early clinical development for success through dosing, biomarker and trial design approaches
- Implementing lessons from ADC clinical trial successes and failures to improve ADC design and clinical outcomes
